Recursion Pharmaceuticals rises as positive Phase 1b/2 trial results for REC-4881 validate AI-driven drug discovery platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
IEEE

Deadlock Resolution and Recursive Feasibility in MPC-Based Multirobot Trajectory Generation

Abstract: Online collision-free trajectory generation within a shared workspace is fundamental for most multirobot applications. However, many widely-used methods based on model predictive control ...
Yahoo Finance

Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data Release - What's Changed

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
GEN

Recursion’s Incoming CEO on Turning AI Drugs Into Clinical Proof Points

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
IEEE

An Efficient Recursive Differential Grouping for Large-Scale Continuous Problems

Abstract: Cooperative co-evolution (CC) is an efficient and practical evolutionary framework for solving large-scale optimization problems. The performance of CC is affected by the variable ...